TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15793459
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid application (initially at home for 2 weeks, followed by higher concentration in-office weekly for six applications)
Study: 15793459
Drug: Multivitamin product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin product (topical application at home daily for 3 months)
Study: 15793459
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base (placebo) for 3 months
Study: 1781798
Drug: Gallopamil (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (0.02 mg/kg/h followed by 0.03 mg/kg/h after 24 hours)
Study: 25119953
Drug: Drug Facts
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Facts
Study: 15329504
Drug: Bepridil alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil alone or in combination with aprindine
Study: 15329504
Drug: Electrical conversion
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical conversion with conventional antiarrhythmic drugs other than bepridil and aprindine
Study: 15329504
Drug: Bepridil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil treatment
Study: 11601567
Drug: AND-HB (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AND-HB (300 mg androstenediol, 480 mg saw palmetto, 450 mg indole-3-carbinol, 300 mg chrysin, 1500 mg gamma-linolenic acid, 1350 mg Tribulus terrestris per day)
Study: 9685822
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg, twice daily for a week)
Study: 9685822
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for a week)
Study: 8027274
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) co-treatment with human menopausal gonadotrophins (HMG) and human chorionic gonadotrophin (HCG)
Study: 797678
Drug: Prophylactic central
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic central nervous system (CNS) therapy
Study: 797678
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic CNS therapy (Control)
Study: 797678
Drug: Prophylactic CNS
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic CNS therapy
Study: 25940329
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose in water solution (group G5W)
Study: 19968380
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with more than 9 sessions
Study: 19968380
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with problem-solving treatment component
Study: 19968380
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with social skills treatment component
Study: 15447898
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg folic acid in a tablet
Study: 11489002
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine (first-line treatment)
Study: 11489002
Drug: Gemcitabine, paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, paclitaxel, and cisplatin or carboplatin (triplet therapy)
Study: 11489002
Drug: Gemcitabine, paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, paclitaxel, and carboplatin (combination treatment)
Study: 3421208
Drug: 5-100 g
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-100 g linseed oil
Study: 3421208
Drug: linolenic acid
Normalized name: Linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: linolenic acid absorption
Study: 27914501
Drug: Intravenous levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levosimendan (0.2 μg kg‐1 min‐1 for the first hour followed by 0.1 μg/kg for 23 hours)
Study: 22013887
Drug: Dual-wave insulin
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-wave insulin boluses for pizza dinner (45g carbohydrates, 400kcal from fat-protein)
Study: 22013887
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group using standard insulin dose calculation (n Carbohydrate Units×ICR)
Study: 20711065
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical and occupational therapy (daily sedative interruption followed by therapy every hospital day)
Study: 16351775
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate syrup (20 mg elemental Fe twice daily) + single dose of vitamin A (33,000 microg)
Study: 16351775
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + single dose of vitamin A (33,000 microg)
Study: 12438295
Drug: no beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: no beta-blockers
Study: 10876850
Drug: Concentrated inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated inactivated tissue-culture tick-borne encephalitis vaccine
Study: 8607736
Drug: EMG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG biofeedback treatment (one 45-minute session)
Study: 8607736
Drug: Additional biofeedback
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional biofeedback treatment sessions (average of 3 sessions)
Study: 21075062
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP™) - 112mg via Novartis T‐326 Inhaler
Study: 21075062
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS, TOBI®) - 300mg/5mL via PARI LC® PLUS nebulizer
Study: 21075062
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP™)
Study: 21075062
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS, TOBI®)
Study: 12468450
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (immunosuppressive drug) paired with a distinctively flavored drink (conditioned stimulus)
Study: 12468450
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules paired with the conditioned stimulus (drink)
Study: 9475269
Drug: molsidomine retard,
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine retard, 8 mg b.i.d.
Study: 9475269
Drug: molsidomine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine, 4 mg t.i.d.
Study: 2797640
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (3 doses of 1-g intravenous cefazolin before, during, and 6-8 hours after surgery)
Study: 15379051
Drug: Verorab vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verorab vaccine (3 intramuscular doses at days 0, 7, and 28)
Study: 15379051
Drug: CRL vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRL vaccine (4 subcutaneous doses at days 0, 3, 7, and 28)
Study: 9580255
Drug: Interferon-alpha2b, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2b, 5 million units, subcutaneously daily for 16 weeks
Study: 9580255
Drug: Prednisone for
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks
Study: 7973768
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and radiation therapy followed by resection
Study: 3057852
Drug: Disopyramide 150
Normalized name: disopyramide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 150 mg 4 times a day
Study: 3057852
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg 4 times a day
Study: 28428187
Drug: Fixed distribution
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed distribution of a coupon to collect HIVST from a drug store or health post
Study: 22782539
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose with dabigatran etexilate 150 mg bid (part 1)
Study: 22782539
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose with dabigatran etexilate 150 mg bid (part 3)
Study: 22782539
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg qd with dabigatran etexilate 150 mg bid (part 2)
Study: 18463543
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (surya namaskara, pranayama, avartan dhyan)
Study: 16129526
Drug: Intranasal proteosome‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal proteosome‐adjuvanted vaccine
Study: 9052356
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline
Study: 14498756
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 or 20 mg (on-demand, not more than once daily)
Study: 16394324
Drug: Priming infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming infusion (5 microg/kg/min) for vecuronium (15 microg/kg)
Study: 16394324
Drug: Higher priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher priming infusion (10 microg/kg/min) for vecuronium (15 microg/kg)
Study: 16394324
Drug: Priming infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming infusion (10 microg/kg/min) for vecuronium (20 microg/kg)
Study: 1783914
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg twice daily (n = 815)
Study: 1783914
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg once daily (n = 806)
Study: 31409421
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-testing (HIVST) provided for eligible household members who are absent or decline testing.
Study: 22488613
Drug: Cemented Exeter
Normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented Exeter implant
Study: 22488613
Drug: Uncemented Zweymüller
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncemented Zweymüller Alloclassic implant
Study: 3893208
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine 100 mg
Study: 9509973
Drug: BUCY (busulfan
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUCY (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg)
Study: 9509973
Drug: BEAC (carmustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEAC (carmustine 300 mg/m2, etoposide 600 mg/m2, cytarabine 600 mg/m2, and cyclophosphamide 140 mg/kg)
Study: 23639822
Drug: Conventional diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diclofenac injection
Study: 21974834
Drug: Multi-professional medication
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-professional medication review at baseline and 6 months
Study: 21974834
Drug: Multi-professional medication
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-professional medication review
Study: 14531810
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic (furosemide or torsemide)
Study: 14531810
Drug: Daily loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily loop diuretic administration
Study: 22316334
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 g kg-1
Study: 22316334
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 g kg-1
Study: 18254150
Drug: Levonorgestrel tablet
Normalized name: Levonorgestrel Tablets
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel tablet formulation 1
Study: 18254150
Drug: Levonorgestrel tablet
Normalized name: Levonorgestrel Tablets
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel tablet formulation 2
Study: 15983467
Drug: Intraoperative remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) (large-dose remifentanil)
Study: 15983467
Drug: Intraoperative remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative remifentanil at 0.05 microg x kg(‐1) x min(‐1) (small-dose remifentanil)
Study: 15983467
Drug: Intraoperative remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) and 0.5 mg/kg ketamine just after induction (large-dose remifentanil-ketamine)
Study: 10624455
Drug: Pamidronate 150
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 150 mg/day
Study: 7575752
Drug: Indometacin 75
Normalized name: Indometacin 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin 75 mg bid
Study: 7575752
Drug: Indometacin 75
Normalized name: Indometacin 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin 75 mg bid plus roxatidine acetate 75 mg nocte
Study: 7575752
Drug: Indometacin 75
Normalized name: Indometacin 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin 75 mg bid plus roxatidine acetate 75 mg bid
Study: 1782227
Drug: UDCA (13‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (13‐15 mg/kg per day)
Study: 20419154
Drug: Telaprevir (HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (HCV protease inhibitor), specific dosage and duration not mentioned
Study: 1813715
Drug: Pseudomonas immunoglobulin
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas immunoglobulin (250 mg/kg) administered intravenously on days 3, 5, 7, 10, and 13 after trauma
Study: 26460306
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive intervention (25 training sessions at home with weekly coaching)
Study: 25325208
Drug: Moderate-dose non-liberal-interval
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose non-liberal-interval dosage (MDNLD) regimen (12.5 mg/Kg every 12 hours)
Study: 25325208
Drug: High-dose extended-interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose extended-interval dosage (HDED) regimen (25 mg/Kg every 24 hours)
Study: 19254942
Drug: AC (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (doxorubicin 40 mg/m2 plus cyclophosphamide 500 mg/m2)
Study: 19254942
Drug: D (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: D (single-agent docetaxel 60 mg/m2)
Study: 17767753
Drug: Bixa Orellana
Normalized name: BIXA ORELLANA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bixa Orellana (BO) 250 mg 3 times a day for 12 months
Study: 3988415
Drug: Potassium +
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium + Magnesium Aspartate (K + Mg Asp)
Study: 30998237
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (0.67 mg/m2/day)
Study: 30004039
Drug: Tadalafil 2.5
Normalized name: tadalafil 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 2.5 mg once daily
Study: 30004039
Drug: Tadalafil 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5.0 mg once daily
Study: 22413962
Drug: Dapagliflozin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin + Metformin
Study: 18338276
Drug: Morphine PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCEA combined with lornoxicam 8 mg iv
Study: 18338276
Drug: Morphine PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCEA combined with placebo (saline 2 ml iv)
Study: 14512205
Drug: Mirtazapine 15-45
Normalized name: mirtazapine 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15-45 mg (n = 124)
Study: 14512205
Drug: Paroxetine 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20-40 mg (n = 122)
Study: 1627434
Drug: Adjuvant intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) - 600 mg/m2 each of cyclophosphamide and fluorouracil, and 40 mg/m2 of methotrexate, administered IV on day 1, repeated every 3 weeks for a total of 12 treatments.
Study: 2861920
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day propranolol
Study: 2861920
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day metoprolol
Study: 27893526
Drug: Supplemental O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental O2 (10 l/min)
Study: 24532523
Drug: Corticosteroid periarticular
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid periarticular injection (40 mg triamcinolone acetonide)
Study: 24532523
Drug: Non-steroid periarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid periarticular injection
Study: 24532523
Drug: Corticosteroid periarticular
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid periarticular injection
Study: 20876699
Drug: Sugammadex 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 0.5 mg kg⁻¹
Study: 20876699
Drug: Sugammadex 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 1.0 mg kg⁻¹
Study: 20876699
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg kg⁻¹
Study: 20876699
Drug: Sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4.0 mg kg⁻¹
Study: 18728368
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of fluoride toothpaste (1,450 ppm F as NaF)
Study: 9656912
Drug: Topical nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroidal anti-inflammatory drug gel (2 g, 5% ibuprofen)
Study: 9656912
Drug: Systemic nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic nonsteroidal anti-inflammatory drug tablets (400 mg ibuprofen)
Study: 9656912
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel and placebo tablets
Study: 2871887
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatments (excluding penicillamine)
Study: 11600576
Drug: Up-regulation of
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-regulation of beta3 integrin subunit by epidermal growth factor or heparin-binding epidermal growth factor.
Study: 11600576
Drug: Adhesion assays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesion assays using Ishikawa cells; alphavbeta3 integrins as primary receptors for osteopontin.
Study: 22592586
Drug: 4-week group
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week group (tenofovir/lamivudine/efavirenz initiated at 4 weeks of TB treatment)
Study: 22592586
Drug: 12-week group
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week group (tenofovir/lamivudine/efavirenz initiated at 12 weeks of TB treatment)
Study: 20569666
Drug: Audiological rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audiological rehabilitation program for SPs (treatment program designed for SPs of PHLs); 90 min sessions, once a week for four weeks.
Study: 20569666
Drug: N/A (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A (control SPs received no treatment).
Study: 20569666
Drug: N/A (experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A (experimental SPs participated in treatment program).
Study: 8994314
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine
Study: 21366801
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis A and B vaccines
Study: 10077020
Drug: OptiMARK (gadoversetamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMARK (gadoversetamide injection)
Study: 7551366
Drug: Formoterol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (24 micrograms twice a day for 2 weeks)
Study: 31088304
Drug: Oral exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exercise in addition to standard general care and diet counseling